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Abstract
Introduction: Preanalytical control and monitoring continue to be an important issue for clinical laboratory professionals. The aim of the study was 
to evaluate a monitoring system of preanalytical errors regarding not suitable samples for analysis, based on different indicators; to compare such 
indicators in different phlebotomy centres; and finally to evaluate a single synthetic preanalytical indicator that may be included in the balanced 
scorecard management system (BSC). 
Materials and methods: We collected individual and global preanalytical errors in haematology, coagulation, chemistry, and urine samples 
analysis. We also analyzed a synthetic indicator that represents the sum of all types of preanalytical errors, expressed in a sigma level. We studied 
the evolution of those indicators over time and compared indicator results by way of the comparison of proportions and Chi-square.
Results: There was a decrease in the number of errors along the years (P < 0.001). This pattern was confirmed in primary care patients, inpatients 
and outpatients. In blood samples, fewer errors occurred in outpatients, followed by inpatients.
Conclusion: We present a practical and effective methodology to monitor unsuitable sample preanalytical errors. The synthetic indicator results 
summarize overall preanalytical sample errors, and can be used as part of BSC management system.
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The main laboratory error source is the preanalyti-
cal phase (1). Preanalytical errors still account for 
60 to 70% of errors that occur in the laboratory, 
and most of them arise during sample collection 
(2). In spite of the laboratory automation, sample 
collection is still fundamentally manual. Frequent 
turnover of the nurses performing phlebotomies, 
shortage of skilled staff, and overloaded systems 
create preventable errors that might compromise 
patient safety, and increase health expenses (3,4). 
The laboratory professionals should minimize the 
possible errors at any phase during the process, in-
cluding sample collection. Besides, it is also neces-
sary to monitor and control this crucial procedure 
in a daily basis to find out if any deviation occur 
and hence to establish different strategies to solve 
but also to prevent the weakness in this crucial 
procedure (5-7). 
Many registers and indicators are generated dur-
ing the entire laboratory process. Solutions, sim-
plifications and modern management tools are 
necessary to monitor and control, to be able at a 
glance to evaluate the total testing process, in or-
der to check the health of the organization at any 
moment. Balanced scorecard (BSC) is a manage-
ment system (8) widely used in private organiza-
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tions that can be applied to clinical laboratories 
(9,10). Initially, BSC was designed by adding to the 
traditional financial indicators, new indicators 
based on 3 additional perspectives: customer, in-
ternal business processes, and learning and 
growth of the organization members (11). By ap-
plying BSC, its use as a means to communicate 
strategy to the organization’s members emerged 
(12). Following further experience, BSC itself be-
came a management system (not only a measure-
ment system), a tool to achieve the organization 
vision. In fact, BSC translates the vision of the or-
ganization into a comprehensive set of quantifia-
ble objectives and performance measures. It is a 
tool for implementing strategy with the help of 
metrics. Through strategies design, indicators tar-
gets and objectives are achieved in every one of 
the four BSC perspectives and hence in the long 
term, the organization vision is also achieved. BSC 
indicators are also classified in four perspectives. 
BSC designers recommended the number of indi-
cators not to exceed 28 - otherwise they will cause 
attention distraction, diminish resource efforts, 
and weaken the strategic focus (11,12) - 7 for each 
perspective, which may not be easy to obtain in 
organizations with complex procedures such as a 
the clinical laboratory. 
Nonetheless, utilization of numerous indicators in 
BSC makes it difficult to achieve a global interpre-
tation. In many situations, the use of fewer but 
more comprehensive indicators is preferable. 
Thereon, some synthetic indicators have been de-
fined that condense the measurement of several 
sub indicators into one value, thereby facilitating 
interpretation and better representing the process 
of healthcare delivery (13).
The hypothesis of the research was that continu-
ous monitoring of preanalytical indicators and the 
use of synthetic indicator could easily help in the 
improvement and monitoring of the laboratory 
processes. The study sought to evaluate a moni-
toring system of preanalytical errors regarding not 
suitable samples for analysis, based on different 
indicators; to compare such indicators in different 
phlebotomy centres; and finally to evaluate a sin-
gle synthetic preanalytical indicator that may be 
included in the BSC management system.
Materials and Methods
Setting
The laboratory is located at the public University 
Hospital of San Juan (Alicante, Spain), a 370-bed 
suburban community hospital that serves a popu-
lation of 234,551 inhabitants, including 9 different 
primary care centres (PCC). It receives samples 
from inpatients, outpatients and primary care pa-
tients. Inpatients’ samples are collected in every 
ward by their nurses and transported to the labo-
ratory and outpatients’ samples are drawn by the 
laboratory and other hospital departments’ nurs-
es. In PCC, nurses obtain samples which are col-
lected by two couriers following scheduled routes 
covering the different PCC and transported to the 
hospital laboratory sample reception desk.
Analysis
This was a retrospective cross-sectional study us-
ing records from January 2003 to December 2012.
A sample error was defined as a rejected speci-
men: any blood or urine sample that could not be 
successfully tested, as it did not meet the accepta-
bility criteria of the laboratory, or a sample that 
was not received (14). 
We collected preanalytical errors from the tests re-
quested in haematology (Ethylenediaminetet-
raacetic acid (EDTA) tube), coagulation (mixture of 
citrate, theophylline, adenosine and dipyridamole 
(CTDA) tube), chemistry (serum tube), and urine 
samples. Specimens that were clotted, insufficient 
(for available technology), hemolysed (15), or un-
collected (sample needed for processing request-
ed tests, but not collected) were included. Only 
preanalytical errors that are frequent and easily af-
fected by sample drawing procedure technical 
problems were chosen for monitoring, because 
those errors were recorded in the Laboratory In-
formation System (LIS) since the beginning of the 
study. Table 1 shows preanalytical errors consid-
ered in each sample. 
When a not suitable sample was identified, a spe-
cific coded result was registered in the LIS as the 
test result in order to report the incident and to re-
quest a new sample. Such coded results were used 
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as the numerator of indicators that were designed 
and classified as individual and global. Individual 
indicators represented the type of preanalytical 
error with respect to every sample collected (three 
for haematology and coagulation, two for chemis-
try, and one for urine samples, as detailed in Table 
2). Additionally, four global indicators, designed as 
the sum of all types of preanalytical errors with re-
spect to every sample collected, were designed 
(urine individual and global indicators are the 
same). The synthetic indicator, which condenses 
the measurement of several sub indicators into 
one value (13,16), represents the sum of all types of 
preanalytical errors with respect to all samples col-
lected. We also calculated an indicator for the total 
blood errors, built as the prior one, without taking 
into account urine samples. In all, 14 indicators 
were considered. 
The indicators registers (coded results and sam-
ples) were collected and indicators calculated us-
ing a software program based on Data Warehouse 
and On-Line Analytical Processing (OLAP) cube 
(Omnium by Roche Diagnostics_ SUNSET Technol-
ogies, Gerona, Spain). 
The number of errors per 10,000 samples was cal-
culated. The number of errors per million samples 
was also calculated in the case of the synthetic in-
dicator and then converted to a sigma level using 
a standard table that gives errors per million sam-
ples values corresponding to sigma levels (17). “Six 
sigma”, referred to the ability of processes to pro-
duce a very high proportion of outputs within 
specification, it comes from the concept that if 
there are six standard deviations between the pro-
cess mean and the nearest specification limit, no 
items will fail to meet process specifications (18).
Samples Preanalytical errors considered
Haematology 
(EDTA tube)
Clotted, insufficient and uncollected
Coagulation 
(CTDA tube)





EDTA - Ethylenediaminetetraacetic; CTDA - mixture of citrate, 
theophylline, adenosine and dipyridamole.
Table 1. Preanalytical errors considered in each sample.
Indicator type Sample Numerator Denominator
Individual Haematology Clotted haematology samples Haematology samples collected
Insufficient haematology samples
Uncollected haematology samples
Coagulation Clotted coagulation samples Coagulation samples collected
Insufficient coagulation samples
Uncollected coagulation samples
Chemistry Hemolysed chemistry samples Chemistry samples collected
Uncollected chemistry samples
Urine* Uncollected urine samples Urine samples collected
Global Haematology (Clotted + Insufficient + Uncollected) haematology 
samples
Haematology samples collected
Coagulation (Clotted + Insufficient + Uncollected) coagulation 
samples
Coagulation samples collected
Chemistry (Hemolysed + Uncollected) chemistry samples Chemistry samples collected
Synthetic All samples All errors in all types of samples All samples collected
Synthetic blood All blood samples All blood errors in all types of samples All blood samples collected
* Urine individual and global indicators are the same
Table 2. Preanalytical indicators.
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Hematology Coagulation Chemistry Urine
2003 93,147 15,455 100,122 41,610
2004 100,349 16,934 106,123 45,596
2005 100,792 21,578 105,335 44,504
2006 105,553 19,588 109,897 47,184
2007 109,315 20,798 112,172 47,398
2008 112,983 20,674 116,521 46,257
2009 109,019 22,728 114,305 42,149
2010 111,191 22,529 115,178 44,585
2011 113,760 22,712 117,081 46,582
2012 109,803 21,378 113,516 44,379
Table 3. Number of haematology, coagulation, chemistry and 
urine samples received annually during the study period.
Statistical analysis
The measures were tabulated in Microsoft Excel 
2007. The differences in indicator results of cate-
gorical responses between two independent 
groups were calculated by way of the comparison 
of proportions and Chi-square. A two-sided P ≤ 
0.05 rule was utilized as the criterion for rejecting 
the null hypothesis of no difference.
Results
In the study period, 1,429,464 requests were re-
ceived and 17,913,071 tests were performed; 
101,534 requests and 2,230,476 tests for inpatients, 
407,600 requests and 5,549,323 tests for outpa-
tients, and 920,330 requests and 10,133,272 tests 
for primary care patients. The detailed number of 
haematology, coagulation, chemistry and urine 
samples received annually during the study peri-
od is shown in Table 3.
Daily, a set of indicators results (individual, global 
and synthetic) are obtained and integrated in lab-
oratory quality system. The annual individual indi-
cators results are shown in Figure 1. The four glob-
al indicators results - as errors per 10,000 samples - 
were significantly (P < 0.001) lower in year 2003 
when compared to 2012 (haematology: 112.07 in 
year 2003 vs. 52.84 in 2012; coagulation 345.52 in 
year 2003 vs. 120.12 in 2012; chemistry 55.53 in year 
2003 vs. 5.46 in 2012; urine 361.45 in year 2003 vs. 
302.62 in 2012). 
The annual global indicator results for inpatients, 
outpatients and primary care patients are shown 
in Figure 2. The greatest number of errors in blood 
samples occurred in primary care patients. Total 
blood errors per 10,000 samples in year 2012 were 
significantly (P = 0.011) higher in primary care pa-
tients (55.84) than in inpatients (52.18) and outpa-
tients (14.19). All annual global indicators results were 
higher in 2003 when compared to 2012 (P < 0.001).
The annual synthetic indicator was again signifi-
cantly (P < 0.001) lower in 2012 (90.14 errors per 
10,000 samples) than in 2003 (144.92 errors per 
10,000 samples). The synthetic indicator results, 
expressed as a sigma level (3.68 in 2003 vs. 3.87 in 
2012), shows the same trend that prior indicator 
results, but in the opposite direction: the higher 
the sigma level, the higher the performance of the 
process, and the lower number of errors and vari-
ability (Figure 3). 
Discussion
The study evaluates a ten year monitoring of pre-
analytical errors regarding not suitable samples 
through quality indicators. There was a decrease 
in the number of errors along the years. The high-
est number of errors occurred in primary care pa-
tients, and the best results were seen in outpa-
tients. We present a synthetic indicator, whose re-
sults reflect trends in the prior specific indicators 
results, as a summary of preanalytical quality. It 
could be included in the BSC management system 
to find out, through the use of a single indicator, if 
the objective of improvement of the preanalytical 
phase is achieved along the years. 
As illustrated by prior investigations (6,7) the first 
key to indicators results reliability, is the use of the 
daily laboratory registers to identify the errors. We 
used the specific codified results, which were in-
dispensable in providing unsuitable test specimen 
results, as a quality record. The automated and 
continuous collection of the LIS quality records 
(specific codified results & samples) and indicators 
calculation by means of the software application 
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based on data warehouse and OLAP cubes is the 
second key to results reliability in the study. The 
use of this technology means that at no time were 
the numbers of errors recorded, collected, or cal-
culated manually. Indeed, the reliability of this 
type of indicators makes them very useful to com-
pare preanalytical errors between different labora-
tories (19).
The trend in sample errors during ten years of 
monitoring reflects the corrective actions carried 
out in order to correct and improve the status, re-
ferred through global indicators of sample errors 
measurement. The actions carried out in order to 
correct and improve the status were educational 
programs for nurses, technological interventions 
to automate manual steps in phlebotomy proce-
dure and promotion of the communication be-
tween the laboratory and peripheral phlebotomy 
centres (6,7). In fact, the synthetic and global indi-
cators provide general information, just a trend in 
the preanalytical errors during the monitoring of 
preanalytical performance. When deviated, in or-
der to implement specific interventions aiming to 
reduce sample errors, each specific indicator 
should be considered.
The observed preanalytical errors in our study 
were similar to that previously published (6,20,21). 
In an attempt to compare our results with those 
from the IFCC working group, we observed that 
we had more errors in hemolysed chemistry sam-
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Figure 1. Annual individual indicators results: Shows each type of preanalytical error with respect to every sample collected (three in 
haematology and coagulation, two in chemistry, and one in urine samples).
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ples and fewer errors in clotted haematology sam-
ples (22). As in the other studies (23), uncollected 
samples were the most frequent problem encoun-
tered. Altogether, there was a decrease in the 
number of errors along the ten years. This pattern 
was confirmed in any setting. Less rate of errors 
occurred in outpatients, followed by inpatients 
and primary care patients. In fact, outpatient’s 
samples showed lower preanalytical errors than 
the primary care patients, despite dealing with 
more seriously ill patients and more complex ex-
aminations. In primary care patients, more errors 
were observed than in the majority of the studies 
(20), which substantiates the influence of the 
blood drawing personnel (24). Besides the person-
nel performing the phlebotomy, it is important to 
consider transport (25,26) and storage conditions 
as an additional source of preanalytical errors. 
Careful handling of the specimen during transport 
and processing is imperative in maintaining the 
quality of a meticulously collected specimen. The 
importance of transport in exposure to heat and 
cold, vibration, position of specimen tubes and 
overall time to delivery can significantly affect test 
results. The rate of errors generated in inpatients 
whose samples are collected by hospital ward 
nurses, were at an intermediate level between 
those observed in PCC and laboratory. The prox-
imity between hospital and laboratory nurses 
should generate an easy and fluid daily communi-
cation that should result in the best results as com-
pared to PCC nurses. This fact confirms the strong 
dependency of preanalytical sample errors on the 
blood drawing personnel: best results are ob-
tained when performed by the laboratory person-
nel (24). To our knowledge this is the first study re-
ferring that better preanalytical results are showed 
the closer is the blood drawing staff to the labora-
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Figure 2. Annual global indicator results in every type of patient: Shows the sum of all types of preanalytical errors with respect to 
every sample collected in inpatients, outpatients and primary care patient’s samples.
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Figure 3. Annual synthetic indicator results: Shows the annual 
synthetic indicator results that represent the sum of all types of 
preanalytical errors with respect to all samples collected calcu-
lated as the number of errors per million samples and convert-
ed to a sigma level.
tory. A critical prerequisite for suitable specimens 
is dependent upon the degree of laboratory su-
pervision of this procedure (3). The training, ability, 
and implication of the professionals are funda-
mental. 
Our study of ten years of preanalytical indicators 
results presents an additional indicator that tries 
to summarize in a single measurement the inci-
dences occurred in all samples. Comparing the re-
sults reported in Figures 2 and 3, it seems evident 
that the synthetic indicator reduces significantly 
the amount of information. However, in order to 
implement specific interventions aiming to reduce 
sample errors, each specific indicator should be 
considered. The global indicator, instead, may pro-
vide general information only, just a trend in the 
preanalytical errors during the monitoring of staff 
performance. Thus, the usefulness of BSC synthet-
ic indicator is as a first step for the efficiency of the 
quality system in the identification and resolution 
of errors. In view of the synthetic indicator results, 
both ways of measurement, through the use of 
defects per million opportunities or six-sigma are 
appropriate, but the latter may be simpler and 
easier to understand. The testing process is com-
plex, consists of numerous steps. As it is common-
ly known, a six-sigma process is one in which 
99.99966% of the outputs are free of defects, com-
pared to a one-sigma process in which only 31% 
are free of defects. The obtained result around a 
sigma level of 4 in just a phase of the total testing 
process, which indicates that the process involved 
is controlled (27). However, once again alerts us 
that we must encourage the improvement in the 
quality of laboratory and hence patient safety. This 
index shows an accurate summary of the individu-
al and global indicators results. Its utility in BSC 
management system seems clear; with one indica-
tor, contained in the BSC Internal procedure per-
spective, it may be possible to monitor preanalyti-
cal outcome over time in a macro level. However, 
the synthetic indicator does not reflect all preana-
lytical errors and its sensitivity is less than individ-
ual indicators.
One limitation is that the study includes some im-
portant preanalytical quality indicators concern-
ing not suitable samples; however, other preana-
lytical errors with respect to missing or incom-
plete/wrong patient identification (28), improper 
transport, handling or sample labelling (wrong 
tube, tube broken, contamination of the sample, 
etc.) were not included (22).
Conclusion
We have presented a practical and effective meth-
od to monitor unsuitable sample preanalytical er-
rors. Fewer errors occurred in outpatients, fol-
lowed by inpatients and primary care patients, 
suggesting that the farther the phlebotomy per-
sonnel from the laboratory, the more frequent the 
errors. Finally the synthetic indicator summarizes 
overall preanalytical sample errors, and can be 
used as part of the BSC management system. The 
implementation of a systematic and continuous 
preanalytical monitoring over time may promote a 
continuous improvement, which will benefit pa-
tient outcome and safety (2).
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